Showing 3571-3580 of 5773 results for "".
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- Orasis Pharmaceuticals Submits NDA for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-submits-nda-for-investigational-novel-eye-drop-candidate-csf-1-for-the-treatment-of-presbyopia/2481315/Orasis Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for investigational CSF-1 (low dose pilocarpine hydrochloride 0.4%). "This NDA submission is a significant milestone for Orasis as we advance CSF-1 towards commercialization and
- Retina Group of New England Joins Retina Consultants of Americahttps://modernod.com/news/retina-group-of-new-england-joins-retina-consultants-of-america/2481314/Retina Consultants of America (RCA) announced it has added
- Outlook Therapeutics Closes $55 Million Financing; Extends Cash Runway Through Anticipated FDA Approval of ONS-5010https://modernod.com/news/outlook-therapeutics-closes-55-million-financing-extends-cash-runway-through-anticipated-fda-approval-of-ons-5010/2481313/Outlook Therapeutics announced it closed on approximately $25 million registered direct equity offering, and about $30 million net proceeds from issuance of an unsecured convertible promissory note with an initial conversion price of $2. The $50 million net proc
- Opus Genetics Acquires Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases from Iveric Biohttps://modernod.com/news/opus-genetics-acquires-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases/2481311/Opus Genetics announced it has acquired the rights to two preclinical-stage AAV-based gene therapy product candidates for inherited retinal diseases (IRDs) from Iveric Bio. Opus will develop the novel gene therapy candidates to address bestrophin-1(BEST1)-related inherited retinal diseases a
- Melt Pharmaceuticals’ MELT-300 Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Studyhttps://modernod.com/news/melt-pharmaceuticals-melt-300-achieves-primary-sedation-endpoint-in-phase-2-pivotal-efficacy-and-safety-study/2481307/Melt Pharmaceuticals announced topline results of its phase 2 pivotal efficacy and safety study for its lead product candidate, MELT-300, a sublingual, needle- and opioid-free patented formulation for procedural sedation during cataract surgery. Based on the outcome of the MELT-300 data, the
- Aldeyra Therapeutics Submits NDA to FDA for ADX‑2191 for Treatment of Primary Vitreoretinal Lymphomahttps://modernod.com/news/aldeyra-therapeutics-submits-new-drug-application-to-fda-for-adx2191-for-treatment-of-primary-vitreoretinal-lymphoma-1/2481306/Aldeyra Therapeutics announced the submission of a new drug application (NDA) to the FDA for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.</
- Iveric Bio Completes Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-announces-completion-of-rolling-nda-submission-to-fda-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481305/Iveric Bio announced that it has submitted to the FDA the third and final part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Staar Surgical CEO Caren Mason to Retire; Tom Frinzi Appointed New CEOhttps://modernod.com/news/staar-surgical-ceo-caren-mason-to-retire-tom-frinzi-appointed-new-ceo/2481302/Staar Surgical announced that President and Chief Executive Officer Caren Mason will be retiring December 31, 2022, after serving in that postion for 7 years. Staar's Board of Directors has appointed ophthalmic industry executive Thomas G. Frinzi, current Board Chair of Staar,
- Verana Health Study of Patients with Dry AMD Published in International Ophthalmologyhttps://modernod.com/news/verana-health-study-of-patients-with-dry-amd-published-in-international-ophthalmology/2481301/Verana Health—a digital health company elevating quality in real-world data—announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has